396 related articles for article (PubMed ID: 11136282)
1. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
Hirschowitz BI; Haber MM
Aliment Pharmacol Ther; 2001 Jan; 15(1):87-103. PubMed ID: 11136282
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with lansoprazole of patients with duodenal ulcer and basal acid output of more than 15 mmol/h.
Hirschowitz BI; Mohnen J; Shaw S
Aliment Pharmacol Ther; 1996 Aug; 10(4):497-506. PubMed ID: 8853753
[TBL] [Abstract][Full Text] [Related]
3. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study.
Hirschowitz BI; Simmons J; Mohnen J
Aliment Pharmacol Ther; 2001 Nov; 15(11):1795-806. PubMed ID: 11683694
[TBL] [Abstract][Full Text] [Related]
4. Minor effects of Helicobacter pylori on gastric secretion and dose of lansoprazole during long-term treatment in ZE and non-ZE acid hypersecretors.
Hirschowitz BI; Simmons J; Mohnen J
Aliment Pharmacol Ther; 2002 Feb; 16(2):303-13. PubMed ID: 11860414
[TBL] [Abstract][Full Text] [Related]
5. Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome.
Hirschowitz BI; Mohnen J; Shaw S
Aliment Pharmacol Ther; 1996 Aug; 10(4):507-22. PubMed ID: 8853754
[TBL] [Abstract][Full Text] [Related]
6. Progression of gastric enterochromaffin-like cells growth in Zollinger-Ellison syndrome and atrophic body gastritis patients.
Delle Fave G; Marignani M; Corleto VD; Angeletti S; D'Ambra G; Ferraro G; D'Adda T; Azzoni C; Jensen RT; Annibale B; Bordi C
Dig Liver Dis; 2002 Apr; 34(4):270-8. PubMed ID: 12038811
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study.
Hirschowitz BI; Simmons J; Mohnen J
Clin Gastroenterol Hepatol; 2005 Jan; 3(1):39-48. PubMed ID: 15645403
[TBL] [Abstract][Full Text] [Related]
8. Chromogranin A in patients with acid hypersecretion and/or hypergastrinaemia.
Hirschowitz BI; Worthington J; Mohnen J; Haber M
Aliment Pharmacol Ther; 2007 Sep; 26(6):869-78. PubMed ID: 17767471
[TBL] [Abstract][Full Text] [Related]
9. Zollinger-Ellison syndrome. Relation to Helicobacter pylori-associated chronic gastritis and gastric acid secretion.
Fich A; Talley NJ; Shorter RG; Phillips SF
Dig Dis Sci; 1991 Jan; 36(1):10-4. PubMed ID: 1984995
[TBL] [Abstract][Full Text] [Related]
10. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia.
Eissele R; Brunner G; Simon B; Solcia E; Arnold R
Gastroenterology; 1997 Mar; 112(3):707-17. PubMed ID: 9041231
[TBL] [Abstract][Full Text] [Related]
11. Treatment of patients with Zollinger-Ellison syndrome.
Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
[TBL] [Abstract][Full Text] [Related]
12. Histopathology of the gastric oxyntic mucosa in two different patient groups during long-term treatment with omeprazole.
Hage E; Hendel L; Gustafsen J; Hendel J
Eur J Gastroenterol Hepatol; 2003 Jul; 15(7):781-9. PubMed ID: 12811309
[TBL] [Abstract][Full Text] [Related]
13. Consequences of long-term proton pump blockade: insights from studies of patients with gastrinomas.
Jensen RT
Basic Clin Pharmacol Toxicol; 2006 Jan; 98(1):4-19. PubMed ID: 16433886
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness and safety of lansoprazole in the treatment of Zollinger-Ellison syndrome. First six months of treatment].
Pospaï D; Cadiot G; Forestier S; Ruszniewski P; Coste T; Escourrou J; Mignon M; Gresze
Gastroenterol Clin Biol; 1998 Oct; 22(10):801-8. PubMed ID: 9854205
[TBL] [Abstract][Full Text] [Related]
15. Studies on the interrelation between Zollinger-Ellison syndrome, Helicobacter pylori, and proton pump inhibitor therapy.
Weber HC; Venzon DJ; Jensen RT; Metz DC
Gastroenterology; 1997 Jan; 112(1):84-91. PubMed ID: 8978346
[TBL] [Abstract][Full Text] [Related]
16. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy.
Sanduleanu S; De Bruïne A; Stridsberg M; Jonkers D; Biemond I; Hameeteman W; Lundqvist G; Stockbrügger RW
Eur J Clin Invest; 2001 Sep; 31(9):802-11. PubMed ID: 11589723
[TBL] [Abstract][Full Text] [Related]
17. Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease.
Stolte M; Meining A; Schmitz JM; Alexandridis T; Seifert E
Aliment Pharmacol Ther; 1998 Mar; 12(3):247-53. PubMed ID: 9570259
[TBL] [Abstract][Full Text] [Related]
18. Idiopathic gastric acid hypersecretion presenting as a diarrheal disorder and mimicking both Zollinger-Ellison syndrome and Crohn's disease.
Blonski WC; Katzka DA; Lichtenstein GR; Metz DC
Eur J Gastroenterol Hepatol; 2005 Apr; 17(4):441-4. PubMed ID: 15756097
[TBL] [Abstract][Full Text] [Related]
19. Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome.
Jensen RT; Metz DC; Koviack PD; Feigenbaum KM
Aliment Pharmacol Ther; 1993; 7 Suppl 1():41-50, discussion 61-6. PubMed ID: 8490079
[TBL] [Abstract][Full Text] [Related]
20. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial.
Fiocca R; Mastracci L; Attwood SE; Ell C; Galmiche JP; Hatlebakk J; Bärthel A; Långström G; Lind T; Lundell L;
Aliment Pharmacol Ther; 2012 Nov; 36(10):959-71. PubMed ID: 22998687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
